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SUMMARY
Background
Lubiprostone (8 lg b.d.) received US Food and Drug Administration
(FDA) approval in 2008 for the treatment of constipation-predominant irri-
table bowel syndrome (IBS-C) in women aged ≥18 years. In 2012, the FDA
issued new guidance for IBS-C clinical trials, recommending a composite
endpoint incorporating both abdominal pain and stool frequency.
Aim
In a post hoc analysis, similar criteria were applied to data from two pivotal,
phase 3, double-blind, randomised trials of lubiprostone in patients with IBS-C.
Methods
Included patients had a baseline spontaneous bowel movement (SBM) fre-
quency <3/week and abdominal pain or bloating ratings ≥1.36 on a 5-point
scale [0 (absent) to 4 (very severe)]. Responders (composite endpoint) had
a mean pain reduction ≥30% compared with baseline, and an increase from
baseline of ≥1 SBM/week for ≥6 of the 12 treatment weeks. Lubiprostone
effects on abdominal pain alone were also evaluated, as were bloating alone
and in a composite endpoint with stool frequency.
Results
In pooled data, 325 patients received lubiprostone and 180 received pla-
cebo. Rates of response were higher with lubiprostone vs. placebo for the
composite endpoint of improved pain and stool frequency (26.3% vs.
15.3%, respectively; P = 0.008) and the composite endpoint of improved
bloating and stool frequency (23.8% vs. 12.6%, respectively; P = 0.012).
Response rates were also higher with lubiprostone vs. placebo for abdomi-
nal pain alone (P = 0.005) and bloating alone (P = 0.012).
Conclusion
Lubiprostone was significantly more effective than placebo in improving
abdominal pain or bloating, and also in composite endpoints that included
stool frequency.
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INTRODUCTION
Irritable bowel syndrome (IBS) is a functional bowel dis-
order that affects approximately 11% of individuals
worldwide.1 The identifying symptoms of IBS are
abdominal pain or discomfort associated with defecation
or altered bowel habits, with supportive symptoms that
may include bloating, straining, a feeling of incomplete
bowel movements and urgency.2 IBS is categorised into
three major subtypes based on stool consistency: IBS
with predominant constipation (IBS-C), IBS with pre-
dominant diarrhoea (IBS-D) or mixed IBS (IBS-M).2, 3
Pharmacological treatment options for patients with
IBS-C are limited,3 as only three agents, including
lubiprostone, have received US Food and Drug Adminis-
tration (FDA) approval, and one was subsequently with-
drawn from US marketing.4, 5 Lubiprostone, an activator
of the ClC-2 chloride channel on the apical surface of
enterocytes in the small intestine, was approved in 2008
for the treatment of IBS-C (8 lg b.d.) in women
≥18 years of age.6 A combined analysis from two pla-
cebo-controlled, 12-week, phase 3 studies found that
lubiprostone treatment was effective and well-tolerated,7
and an open-label extension study demonstrated a
favourable safety and tolerability profile, and preliminary
evidence of long-term efficacy.3 The primary efficacy
endpoint in these studies was calculated from weekly
assessments of symptom relief based on a balanced scale
ranging from significantly worse to significantly relieved.7
Monthly responders were defined as those who rated IBS
symptoms as being at least moderately relieved for all
weeks or significantly relieved for at least half of the
weeks of the given month.7 In addition, responders could
not rate symptoms as moderately or significantly worse.7
A patient was considered an overall responder if they
were a monthly responder for at least two of the three
study months.7 This endpoint has been considered
relatively stringent.
In 2012, after the approval of lubiprostone for IBS-C,
the FDA issued a new guidance for industry for clinical
studies in patients with IBS that recommended changes
to study entry criteria and endpoints.8 Current guidance
recommends that patients eligible for clinical studies of
IBS-C have a weekly average of worst daily abdominal
pain (in past 24 h) score of ≥3.0 on a 0–10 scale and ≤3
complete spontaneous bowel movements (CSBMs) per
week.8 Regarding study endpoints, prior studies used
assessments such as the single-item Subject’s Global
Assessment of Relief of IBS symptoms; these endpoints
do not provide detailed symptom evaluations. Current
guidance recommends the use of composite endpoints
that measure the effect of treatment on abdominal pain
and stool frequency, major defining features of IBS-C.9
Treatment response is defined as achievement of a
decrease ≥30% in weekly average score of worst abdomi-
nal pain in the past 24 h compared with baseline and an
increase of ≥1 CSBM per week compared with baseline
for ≥50% of treatment days or weeks.8
In consideration of the updated FDA guidance, we
retrospectively analysed data from the two pivotal, pla-
cebo-controlled, phase 3 studies of lubiprostone in
patients with IBS-C. The efficacy of lubiprostone for
abdominal pain was assessed in patients with a baseline
level of abdominal pain as specified in current guidance.
The efficacy of lubiprostone for patients with abdominal
bloating at baseline was similarly assessed. Finally, we
evaluated the efficacy of lubiprostone using a composite
endpoint of abdominal pain and stool frequency, reflect-
ing current FDA recommendations for treatment
response. A composite endpoint of bloating and stool
frequency was also evaluated.
METHODS
This post hoc analysis included data from two similarly
designed phase 3, double-blind, randomised, placebo-
controlled studies of lubiprostone in patients with
IBS-C (NCT00380250, NCT00399542). Study designs
have been described in detail previously.7 Briefly, the
studies consisted of a 4-week baseline/screening period
and a 12-week treatment period in which patients were
randomised to receive either lubiprostone (8 lg b.d.) or
placebo.7 Patients in these pooled studies included men
and women (nonpregnant and nonlactating) ≥18 years
of age meeting the Rome II Modular Questionnaire cri-
teria for IBS-C.7 Patients who were excluded had previ-
ous gastrointestinal or abdominal surgery (except for
common causes unrelated to IBS); organic disorders of
the small or large intestine (e.g. ulcerative colitis,
Crohn’s disease); mechanical obstruction; or any medi-
cal condition associated with constipation other than
IBS.7
Efficacy analyses
Each study was analysed separately and as a pooled anal-
ysis. All included patients had a spontaneous bowel
movement (SBM) frequency <3/week at baseline.
Improvement in abdominal pain by baseline abdominal
pain score and improvement in bloating by baseline
bloating score were evaluated in patients with baseline
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pain scores or baseline bloating scores, respectively, of
≥1.36 on a 5-point scale [0 (absent) to 4 (very severe)].
A score of ≥1.36 on a 5-point scale corresponds to the
current FDA-recommended trial entry criteria of baseline
pain score of ≥3 on an 11-point scale (0–10).8 In order
to determine whether there were differential effects of
lubiprostone related to different baseline pain or baseline
bloating severity scores, subgroups of patients with
respective baseline scores of ≥1.5, ≥2.0, ≥2.5 and ≥3.0
were also evaluated. Responders were defined as patients
with ≥30% improvement (mean reduction in pain or
bloating compared with baseline) for ≥6 weeks of the
12-week treatment period.
Changes in abdominal pain and stool frequency were
analysed as composite endpoints to match the treatment
responder definition recommended by the FDA. A com-
posite endpoint of bloating and stool frequency was also
evaluated. Composite endpoints were analysed in a sim-
ilar manner as individual endpoints (i.e. patients
included in this analysis also had baseline pain or base-
line bloating scores of ≥1.36 on a 5-point scale and sub-
groups of patients with respective baseline scores of
≥1.5, ≥2.0, ≥2.5 and ≥3.0 were evaluated). Responders
were defined as those having a mean pain or bloating
score reduction ≥30% compared with baseline and an
increase from baseline of ≥1 SBM/week for ≥6 of the 12
treatment weeks. Complete SBMs were not analysed
because completeness of evacuation was not included as
one of the assessments at the time these studies were
conducted, which was prior to the issuance of FDA
guidance.
Safety assessments
Treatment-emergent adverse events (AEs) were recorded
and evaluated for severity and relationship with treatment.
Statistical analyses
Efficacy analyses were performed in the intent-to-treat
(ITT) population, defined as patients who were ran-
domised to double-blind treatment and received ≥1 dose
of study medication. The Cochran–Mantel–Haenszel test
stratified by pooled site was used to determine differ-
ences in response rates between patients treated with
lubiprostone and those who received placebo. The last
observation carried forward method was used to impute
missing efficacy data. Safety analysis was performed in
the safety population, defined as patients who received
≥1 dose of study medication; the analysis is based on the
actual treatment received.
RESULTS
Patients
The pooled ITT population with SBM frequency
<3/week at baseline included 505 patients who were ran-
domised to double-blind lubiprostone treatment (8 lg
b.d.; n = 325) or placebo (n = 180; Figure 1). Study 1
consisted of 170 and 88 patients randomised to lubipros-
tone treatment or placebo, respectively, and Study 2 con-
sisted of 155 and 92 patients randomised to lubiprostone
treatment or placebo respectively. In placebo and
lubiprostone-treatment patients combined, 68 (26.4%)
and 54 (21.9%) patients discontinued therapy in Study 1
and Study 2 respectively. Demographic and baseline dis-
ease characteristics of patients in the ITT population
were generally well balanced between the placebo and
lubiprostone groups, as well as across the individual
studies and the pooled analysis (Table 1). However, there
was a significant difference in Study 2 for mean (s.d.)
SBM frequency/week between patients who received
lubiprostone [1.55 (0.87)] vs. placebo [1.32 (0.94)],
P < 0.05.
Abdominal pain and the response to lubiprostone
Response rates in the pooled population with a baseline
pain score ≥1.36 were significantly higher for patients
who received lubiprostone vs. placebo [36.7% (106/289)
vs. 25.2% (41/163); P = 0.005; Figure 2]. Response rates
with lubiprostone were also higher vs. placebo in patients
with baseline abdominal pain scores ≥1.5, ≥2.0, ≥2.5, and
≥3.0, but possibly because of the small number of
patients with a baseline pain score of ≥3.0, the response
rate was not significant at the highest baseline pain level.
In the individual studies, treatment response rates
between patients with a baseline pain score ≥1.36 who
received lubiprostone vs. placebo were not significantly
different; Study 1: 35.3% (54/153) vs. 24.7% (19/77)
respectively; Study 2: 38.2% (52/136) vs. 25.6% (22/86)
respectively (Table S1). Although not statistically signifi-
cant, the treatment response rates of the individual stud-
ies were similar to the response rates observed in the
pooled study population.
Bloating and the response to lubiprostone
Response rates in the pooled population with a baseline
bloating score ≥1.36 were significantly higher in patients
receiving lubiprostone compared with placebo [32.0%
(97/303) vs. 20.4% (42/167); P = 0.012; Figure 3). In
patients with higher baseline bloating scores (≥1.5, ≥2.0,
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≥2.5 and ≥3.0), response rates with lubiprostone
remained significantly higher than with placebo, except
in patients in the ≥2.5 and ≥3.0 subgroups where a
numerical difference was observed. In Study 2, treatment
response rates between patients with a baseline bloating
score ≥1.36 who received lubiprostone vs. placebo were
significantly different [34.5% (48/139) vs. 17.2% (15/87)
respectively; P = 0.019]; however, the difference in Study
1 was not significant [29.9% (49/164) vs. 23.8% (19/80)
respectively (Table S2)].
Composite endpoints
Abdominal pain and stool frequency. Composite response
rates were significantly higher in the pooled population
with a baseline pain score ≥1.36 who received lubiprostone
vs. placebo [26.3% (76/289) vs. 15.3% (25/163); P = 0.008;
Figure 4]. Response rates with lubiprostone remained
significantly higher vs. placebo in patients in baseline
abdominal pain subgroups ≥1.5 and ≥2.0, but not in the
≥2.5 and ≥3.0 subgroups, where a numerical difference
was observed. In Study 1, composite response rates
between patients with a baseline pain score ≥1.36 who
received lubiprostone vs. placebo were significantly dif-
ferent [25.5% (39/153) vs. 13.0% (10/77) respectively;
P = 0.034]; however, the difference in Study 2 was not
significant [27.2% (37/136) vs. 17.4% (15/86) respec-
tively], although absolute differences between lubipros-
tone and placebo response rates were similar in the two
studies (Table S3).
Bloating and stool frequency. Composite response rates
in the pooled population with baseline bloating score
≥1.36 were significantly higher for patients who received
lubiprostone vs. placebo [23.8% (72/303) vs. 12.6% (21/
167); P = 0.012; Figure 5]. Response rates with lubipros-
tone remained higher vs. placebo for patients in baseline
bloating score subgroups ≥1.5 and ≥2.0, but not in the
≥2.5 and ≥3.0 subgroups, where a numerical difference
was observed. Composite response rates for patients with
a baseline bloating score ≥1.36 were not significantly dif-
ferent between patients who received lubiprostone vs. pla-
cebo in Study 1 [23.2% (38/164) vs. 13.8% (11/80)
respectively] or Study 2 [24.5% (34/139) vs. 11.5% (10/87)
respectively (Table S4)].
Pooled safety evaluation
At least one treatment-emergent AE was reported by
49.4% of patients who received lubiprostone and 45.3%
Total enrollment
n = 505
Lubiprostone Placebo
n = 170
Lubiprostone
n = 155
n = 170
n = 92
n = 92
Placebo
n = 88
n = 88
ITT
Discontinuation
n = 25 (27.2%)
Adverse events – 8.7%
Lack of efficacy – 6.5%
Lost to follow-up – 5.4%
Non-compliance – 2.2%
Other – 0.0%
Voluntary
withdrawal – 4.3%
Protocol violation – 0.0%
Discontinuation
n = 29 (18.7%)
Adverse events – 3.2%
Lack of efficacy – 3.9%
Lost to follow-up – 1.9%
Non-compliance – 2.6%
Other – 0.6%
Voluntary
withdrawal – 5.8%
Protocol violation – 0.6%
Discontinuation
n = 42 (24.7%)
Adverse events – 5.3%
Lack of efficacy – 0.6%
Lost to follow-up – 2.9%
Non-compliance – 4.1%
Other – 1.8%
Voluntary
withdrawal – 10.0%
Protocol violation – 0.0%
Discontinuation
n = 26 (29.5%)
Adverse events – 2.3%
Lack of efficacy – 4.5%
Lost to follow-up – 3.4%
Non-compliance – 3.4%
Other – 1.1%
Voluntary
Protocol violation – 1.1%
Completion rate – 70.5% Completion rate – 75.3% Completion rate – 72.8% Completion rate – 81.3%
ITT ITT
n = 155
ITT
n = 258
Study 1 Study 2
n = 247
withdrawal – 13.6%
Figure 1 | Patient disposition. ITT, intent-to-treat population.
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who received placebo. The most frequently reported
treatment-emergent AEs in the overall pooled population
were gastrointestinal in nature and included nausea
(7.9%), diarrhoea (4.4%) and abdominal pain (4.4%).
The frequency of these AEs in patients receiving lubipro-
stone treatment vs. placebo, respectively, were nausea,
9.3% vs. 5.5%; diarrhoea, 4.9% vs. 3.3%; and abdominal
pain, 3.7% vs. 5.5%. Of note, one patient in the pooled
Table 1 | Baseline demographic and clinical characteristics in two randomised, controlled studies of lubiprostone in
patients with baseline SBM frequency <3/week (intent-to-treat populations)
Study 1 Study 2 Pooled Studies
Placebo
(n = 88)
Lubiprostone
(n = 170)
Placebo
(n = 92)
Lubiprostone
(n = 155)
Placebo
(n = 180)
Lubiprostone
(n = 325)
Sex, n (%)
Female 85 (96.6) 161 (94.7) 89 (96.7) 143 (92.3) 174 (96.7) 304 (93.5)
Male 3 (3.4) 9 (5.3) 3 (3.3) 12 (7.7) 6 (3.3) 21 (6.5)
Mean (s.d.) age, years 47.6 (12.4) 45.8 (12.9) 45.3 (12.0) 44.8 (11.8) 46.4 (12.2) 45.4 (12.4)
Race/ethnicity, n (%)
White 64 (72.7) 117 (68.8) 68 (73.9) 112 (72.3) 132 (73.3) 229 (70.5)
Black/African American 16 (18.2) 28 (16.5) 17 (18.5) 33 (21.3) 33 (18.3) 61 (18.8)
Hispanic/Latino 7 (8.0) 25 (14.7) 7 (7.6) 10 (6.5) 14 (7.8) 35 (10.8)
Other 1 (1.1) 0 0 0 1 (0.6) 0
Mean (s.d.) abdominal
discomfort/pain*
2.18 (0.69) 2.27 (0.67) 2.25 (0.63) 2.14 (0.70) 2.21 (0.66) 2.21 (0.69)
Mean (s.d.) bloating* 2.37 (0.69) 2.48 (0.69) 2.40 (0.62) 2.30 (0.74) 2.39 (0.65) 2.39 (0.72)
Mean (s.d.) SBM
frequency/week
1.49 (0.85) 1.56 (0.91) 1.32 (0.94) 1.55 (0.87)† 1.40 (0.90) 1.56 (0.89)
SBM, spontaneous bowel movement.
P values were calculated using a 2-sample t-test for continuous variables and a chi-square test for categorical variables.
* Scale from 0 (absent) to 4 (very severe).
† P < 0.05 vs. placebo.
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Figure 2 | Treatment response rates in patients with baseline abdominal pain scores ≥1.36. Treatment response defined
as ≥30% improvement in abdominal pain vs. baseline for ≥6 of 12 treatment weeks by baseline abdominal pain score
(pooled data). *P < 0.01. †P < 0.05. ‡Equivalent to 3 on a scale of 0–10. §Scale from 0 (absent) to 4 (very severe).
P values compare placebo vs. lubiprostone, based on the Cochran–Mantel–Haenszel test stratified by pooled site.
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population, a patient who received lubiprostone, experi-
enced an AE of severe diarrhoea. Study discontinuation
due to diarrhoea occurred in two patients overall, one
who received placebo and one who was treated with
lubiprostone.
DISCUSSION
In this analysis, treatment with lubiprostone significantly
improved abdominal pain compared with placebo in
patients with a baseline abdominal pain level corre-
sponding to the current FDA-recommended trial entry
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Figure 3 | Treatment response rates in patients with baseline bloating scores ≥1.36. Treatment response defined as
≥30% improvement in bloating vs. baseline for ≥6 of 12 treatment weeks by baseline bloating score (pooled data).
*P < 0.05. †P < 0.01. ‡Equivalent to 3 on a scale of 0–10. §Scale from 0 (absent) to 4 (very severe). P values compare
placebo vs. lubiprostone, based on the Cochran–Mantel–Haenszel test stratified by pooled site.
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Figure 4 | Treatment response rates in patients with baseline abdominal pain scores ≥1.36 using a composite
endpoint. Composite treatment response defined as ≥30% improvement in abdominal pain and ≥1 increase in
spontaneous bowel movements per week vs. baseline for ≥6 of 12 treatment weeks by baseline abdominal pain score
(pooled data). *P < 0.01. †P < 0.05. ‡Equivalent to 3 on a scale of 0–10. §Scale from 0 (absent) to 4 (very severe).
P values compare placebo vs. lubiprostone, based on the Cochran–Mantel–Haenszel test stratified by pooled site.
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criteria for baseline abdominal pain. Furthermore,
lubiprostone significantly improved bloating vs. placebo
in patients with a baseline bloating score of ≥1.36 on a
5-point scale, a baseline bloating level that corresponds
to that recommended by the FDA for baseline abdomi-
nal pain. Response rates for the composite endpoint rec-
ommended by current guidance, improvement in
abdominal pain and stool frequency, were significantly
higher in patients who received lubiprostone compared
with those who received placebo. Response rates for the
composite endpoint of bloating and stool frequency also
were higher with lubiprostone treatment vs. placebo.
The effects of lubiprostone vs. placebo were explored
in subgroups of patients with higher intensity pain or
bloating scores at baseline (≥1.5, ≥2.0, ≥2.5 and ≥3.0 on
a 5-point scale) than those corresponding to the FDA
entry criteria (≥1.36 on a 5-point scale). In the pooled
analyses, significant differences favouring lubiprostone
treatment vs. placebo were seen in patient subgroups
with higher baseline pain or bloating scores (e.g. those
with scores ≥2.0 at baseline), and absolute differences in
response rates with lubiprostone vs. placebo were larger
in subgroups with higher baseline pain or bloating
scores. Lack of statistical significance in subgroups with
baseline scores of ≥2.5 or ≥3.0 may be related to small
sample sizes (the number of patients in each subgroup
decreased with increased baseline score) as the difference
in effect size between the study arms was preserved in
these subgroups.
Safety findings from the two pivotal studies have been
described elsewhere.7 In this pooled analysis, as has been
reported, the most common AEs were gastrointestinal,
and lubiprostone was generally well-tolerated. Severe
diarrhoea and study discontinuation due to diarrhoea
were seldom seen; each occurred in one patient who had
received lubiprostone. In a randomised, 26-week study of
linaclotide, diarrhoea was the most common treatment-
emergent AE, occurring significantly more often with
linaclotide (19.7%; 79/402) compared with placebo
(2.5%; 10/403). A total of eight patients (2%) experienced
severe diarrhoea with linaclotide vs. none with placebo,
and linaclotide was associated with study drug discontin-
uation in 18 patients (4.5%) who received linaclotide and
one patient (0.2%) who received placebo.10 Lubiprostone
and linaclotide have not been compared directly in the
same population; however, the available evidence sug-
gests that diarrhoea is not a concern with lubiprostone
treatment.
We faced a number of challenges in retrospectively
applying current FDA guidance to our lubiprostone data
set. Among the most important was that SBMs, not
CSBMs (current guidance), were collected as an endpoint
in lubiprostone studies. In studies which evaluated lina-
clotide in patients with IBS-C, the relative difference
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Figure 5 | Treatment response rates in patients with baseline bloating scores ≥1.36, using a composite endpoint.
Composite treatment response defined as ≥30% improvement in bloating and ≥1 increase in spontaneous bowel
movements per week vs. baseline for ≥6 of 12 treatment weeks by baseline abdominal pain score (pooled data).
*P < 0.05. †Equivalent to 3 on a scale of 0–10. ‡Scale from 0 (absent) to 4 (very severe). P values compare placebo
vs. lubiprostone, based on the Cochran–Mantel–Haenszel test stratified by pooled site.
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between SBM vs. CSBM frequency at baseline was
approximately 1:9.10, 11 Regarding change in SBM com-
pared with CSBM frequency with treatment, however,
the percentage of patients who experienced ≥1 increase
in SBMs per week with linaclotide was approximately
1.5–2 times higher than the percentage who experienced
≥1 increase in CSBM.10, 11 These results suggest that a
composite measure using SBMs would lead to a higher
responder rate than if CSBMs were used. However, it
should be noted that entry criteria for the lubiprostone
studies compared with more recent studies were quite
different even in the selected population analysed here
(patients had to have an SBM frequency <3/week at
baseline), and the baseline weekly SBM frequency was
1.5, which is lower than in patients who participated in
studies of linaclotide (1.8).11 Therefore, a ≥1 increase in
SBMs per week in lubiprostone studies could be a
clinically relevant finding.
Finally, the dose of lubiprostone (8 lg b.d.) used in
pivotal phase 3 studies and approved for the treatment of
IBS-C is lower than the 24 lg b.d. dose of lubiprostone
that is approved for the treatment of patients with chronic
idiopathic constipation or opioid-induced constipation.6
The lower dose of lubiprostone used in these IBS-C stud-
ies compared with the dose approved for patients with
chronic idiopathic constipation or opioid-induced consti-
pation may play a role in the 10–14% lower response rate
observed using the composite endpoint compared with
using the abdominal pain only responder definition. In a
phase 2 dose-ranging trial evaluating the efficacy of
lubiprostone in IBS-C, the 24 lg, but not 8 lg, b.d.
dosage was associated with significantly greater improve-
ment in abdominal pain/discomfort scores vs. placebo at
month 1, although both doses showed similar improve-
ment in months 2–3.12 However, the higher dose of
lubiprostone was also associated with a higher incidence
of adverse events and as such the 8 lg b.d. dose is consid-
ered optimal for providing the benefit of efficacy with
limited (low incidence and intensity) adverse events in
IBS-C. It should be noted that the lubiprostone IBS-C
studies were designed in accordance with Rome II criteria,
which defined the hallmark symptom of IBS as abdominal
pain, with reduced stool frequency as one of a number of
criteria that a patient may report in order to qualify for
an IBS diagnosis.13
In conclusion, lubiprostone was significantly more
effective than placebo in improving abdominal pain
based on baseline abdominal pain scores, and bloating
based on baseline bloating scores. Despite the challenges
involved in applying new criteria to historical data,
treatment with lubiprostone significantly improved the
composite endpoint of improvements in abdominal pain
(by baseline pain scores) and stool frequency in patients
with IBS-C. A composite endpoint evaluating improve-
ment in bloating (by baseline bloating score) and stool
frequency also found lubiprostone to be significantly
more effective than placebo. These results were achieved
despite the trials having been designed to apply a dose
(8 lg b.d.) more suitable for treatment of pain; this dose
was lower than one that would have been administered
with the intention of showing a more profound effect on
bowel movement frequency.
SUPPORTING INFORMATION
Additional Supporting Information may be found in the
online version of this article:
Table S1. Treatment response rate (percentage of
patients with ≥30% improvement in abdominal pain vs.
baseline for ≥6 of 12 treatment weeks by baseline
abdominal pain score) in Studies 1 and 2 in patients
with baseline abdominal pain scores ≥1.36.
Table S2. Treatment response rate (percentage of
patients with ≥30% improvement in bloating vs. baseline
for ≥6 of 12 treatment weeks by baseline bloating score)
in Studies 1 and 2 in patients with baseline bloating
scores ≥1.36.
Table S3. Treatment response rate in Studies 1 and 2
in patients with baseline abdominal pain scores ≥1.36
using a composite endpoint defined as ≥30% improve-
ment in abdominal pain and ≥1 increase in spontaneous
bowel movements per week vs. baseline for ≥6 of 12
treatment weeks by baseline abdominal pain score.
Table S4. Treatment response rate in patients with
baseline bloating scores ≥1.36, using a composite end-
point in Studies 1 and 2 defined as ≥30% improvement
in bloating and ≥1 increase in spontaneous bowel move-
ments per week vs. baseline for ≥6 of 12 treatment weeks
by baseline abdominal pain score.
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